Molecular landscape of eyelid sebaceous gland carcinoma: A comprehensive review.

Publisher: Medknow Publications Country of Publication: India NLM ID: 0405376 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1998-3689 (Electronic) Linking ISSN: 03014738 NLM ISO Abbreviation: Indian J Ophthalmol Subsets: MEDLINE

Publication: Mumbai : Medknow Publications
Original Publication: Bombay : All-India Ophthalmological Society

Eyelid Neoplasms*/metabolism ; Eyelid Neoplasms*/genetics ; Eyelid Neoplasms*/diagnosis ; Sebaceous Gland Neoplasms*/genetics ; Sebaceous Gland Neoplasms*/metabolism ; Sebaceous Gland Neoplasms*/diagnosis ; Adenocarcinoma, Sebaceous*/metabolism ; Adenocarcinoma, Sebaceous*/genetics ; Adenocarcinoma, Sebaceous*/diagnosis ; Adenocarcinoma, Sebaceous*/pathology; Humans ; Biomarkers, Tumor/metabolism ; Biomarkers, Tumor/genetics ; Mutation

Eyelid sebaceous gland carcinoma (SGC) is an aggressive skin cancer characterized by a heightened risk of recurrence and metastasis. While surgical excision is the primary treatment, unraveling the molecular intricacies of SGC is imperative for advancing targeted therapeutic interventions and enhancing patient outcomes. This comprehensive review delves into the molecular landscape of eyelid SGC, emphasizing key genetic alterations, signaling pathways, epigenetic modifications, and potential therapeutic targets. Significant findings include aberrations in critical signaling pathways (β-catenin, lymphoid enhancer binding factor, hedgehog, epidermal growth factor receptor, P53, and P21WAF1) associated with SGC progression and poor prognosis. Notably, eyelid SGC manifests a distinctive mutational profile, lacking ultraviolet signature mutations in tumor protein 53 (TP53), indicating alternative mutagenic mechanisms. Next-generation sequencing identifies actionable mutations in genes such as phosphatase and tensin homolog (PTEN) and Erb-B2 receptor tyrosine kinase 2 (ERBB2), facilitating the emergence of personalized medicine approaches. Molecular chaperones, specifically X-linked inhibitor of apoptosis protein (XIAP) and BAG3, emerge as pivotal players in promoting tumor survival and proliferation. The review underscores the role of epithelial-mesenchymal transition, where regulators like E-cadherin, vimentin, and ZEB2 contribute to SGC aggressiveness. Epigenetic modifications, encompassing DNA methylation and microRNA dysregulation, further elucidate the molecular landscape. This review consolidates a comprehensive understanding of the molecular drivers of eyelid SGC, shedding light on potential therapeutic targets and providing a foundation for future investigations in diagnostic, prognostic, and personalized treatment strategies for this formidable malignancy.
(Copyright © 2024 Copyright: © 2024 Indian Journal of Ophthalmology.)

Oman J Ophthalmol. 2018 Jan-Apr;11(1):21-27. (PMID: 29563690)
Indian J Ophthalmol. 2017 Nov;65(11):1109-1113. (PMID: 29133634)
Eye (Lond). 2006 Oct;20(10):1165-70. (PMID: 17019414)
Hum Pathol. 2014 Mar;45(3):533-9. (PMID: 24440092)
Invest Ophthalmol Vis Sci. 2015 Feb 24;56(3):1813-9. (PMID: 25711631)
Sci Rep. 2018 May 14;8(1):7531. (PMID: 29760516)
Hum Pathol. 2015 Oct;46(10):1437-42. (PMID: 26220160)
Int J Radiat Oncol Biol Phys. 2023 Jul 15;116(4):858-868. (PMID: 36690161)
Mod Pathol. 2020 Jul;33(7):1256-1263. (PMID: 31937901)
Am J Dermatopathol. 2011 Aug;33(6):579-87. (PMID: 21778832)
Head Neck. 2013 May;35(5):642-8. (PMID: 22715107)
Ophthalmic Plast Reconstr Surg. 2014 Sep-Oct;30(5):392-5. (PMID: 24777261)
Transl Oncol. 2020 Jun;13(6):100773. (PMID: 32334405)
Can J Ophthalmol. 2019 Dec;54(6):688-693. (PMID: 31836101)
Eye (Lond). 1999;13 ( Pt 1):104-8. (PMID: 10396393)
Ophthalmology. 2001 Jun;108(6):1124-8. (PMID: 11382640)
J Immunother Cancer. 2018 Jun 19;6(1):58. (PMID: 29914578)
Ophthalmology. 2004 Dec;111(12):2151-7. (PMID: 15582067)
Ophthalmic Plast Reconstr Surg. 2004 Jan;20(1):31-6. (PMID: 14752307)
Dev Biol. 2007 Feb 1;302(1):1-12. (PMID: 16989803)
J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):279-80. (PMID: 1430382)
Eye (Lond). 1999;13 ( Pt 1):109-10. (PMID: 10396394)
J Pathol. 2016 Sep;240(1):84-95. (PMID: 27287813)
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):605-11. (PMID: 21300468)
Orbit. 2012 Jun;31(3):150-4. (PMID: 22551364)
Br J Dermatol. 2012 Sep;167(3):583-90. (PMID: 22458737)
Ann Transl Med. 2022 May;10(9):517. (PMID: 35928738)
Indian J Ophthalmol. 2019 Dec;67(12):1983-1987. (PMID: 31755433)
Antibodies (Basel). 2019 Oct 21;8(4):. (PMID: 31640266)
Nat Commun. 2018 May 14;9(1):1894. (PMID: 29760388)
J Dermatol. 2011 Oct;38(10):951-8. (PMID: 21592202)
Indian J Ophthalmol. 2022 Feb;70(2):633-634. (PMID: 35086252)
Int J Dermatol. 2017 Jul;56(7):746-749. (PMID: 28181233)
Ocul Oncol Pathol. 2021 Sep;7(4):251-256. (PMID: 34604196)
Br J Ophthalmol. 2010 Oct;94(10):1316-21. (PMID: 20530655)
Mod Pathol. 2011 Sep;24(9):1248-53. (PMID: 21552211)
Ophthalmic Plast Reconstr Surg. 2011 Jan-Feb;27(1):e4-6. (PMID: 20940661)
Ophthalmic Plast Reconstr Surg. 2016 Jan-Feb;32(1):35-9. (PMID: 25675161)
J Clin Neurosci. 2009 Apr;16(4):568-70. (PMID: 19200735)
Surv Ophthalmol. 2005 Mar-Apr;50(2):103-22. (PMID: 15749305)
Biomolecules. 2020 Oct 29;10(11):. (PMID: 33138314)
J Cutan Pathol. 2009 Jun;36(6):613-9. (PMID: 19515040)
Int Ophthalmol. 2019 May;39(5):1187-1197. (PMID: 29696467)
Cancer Res. 2007 Apr 1;67(7):2916-21. (PMID: 17409394)
Am J Ophthalmol. 2013 Jul;156(1):43-49.e2. (PMID: 23628352)
J Radiat Res. 2019 Oct 23;60(5):622-629. (PMID: 31271440)
Ophthalmic Plast Reconstr Surg. 2008 May-Jun;24(3):194-200. (PMID: 18520834)
Br J Ophthalmol. 2011 Dec;95(12):1686-90. (PMID: 21979897)
Lancet. 2021 Sep 11;398(10304):1002-1014. (PMID: 34509219)
Am J Dermatopathol. 2015 Nov;37(11):809-21. (PMID: 26485238)
Nat Med. 2006 Apr;12(4):395-7. (PMID: 16565724)
Am J Ophthalmol. 2014 Mar;157(3):640-7.e1-2. (PMID: 24321472)
Br J Ophthalmol. 2020 Jun;104(6):879-884. (PMID: 30940620)
Can J Ophthalmol. 2014 Aug;49(4):326-32. (PMID: 25103648)
Br J Dermatol. 2015 Sep;173(3):811-4. (PMID: 25639559)
Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11873-80. (PMID: 12917489)
Eye (Lond). 2015 Jul;29(7):958-63. (PMID: 25998946)
Ophthalmic Plast Reconstr Surg. 2007 Jan-Feb;23(1):77-9. (PMID: 17237705)
Ophthalmic Plast Reconstr Surg. 2018 Sep/Oct;34(5):e149-e151. (PMID: 29979269)
Br J Ophthalmol. 2021 Jan;105(1):48-56. (PMID: 32277010)
Mol Med Rep. 2021 Jan;23(1):. (PMID: 33179085)
Eye (Lond). 2004 Jan;18(1):49-53. (PMID: 14707966)
iScience. 2023 May 05;26(6):106816. (PMID: 37235052)
Br J Ophthalmol. 2019 Jul;103(7):980-984. (PMID: 30131380)
Indian J Ophthalmol. 2016 Mar;64(3):177-90. (PMID: 27146927)
Ophthalmology. 2002 Nov;109(11):2129-33. (PMID: 12414427)
Br J Ophthalmol. 2017 Apr;101(4):536-542. (PMID: 28119291)
Cancers (Basel). 2021 Sep 26;13(19):. (PMID: 34638295)
J Clin Pathol. 2006 Nov;59(11):1166-70. (PMID: 16556662)
J Pathol. 2009 Dec;219(4):427-34. (PMID: 19621338)
Br J Ophthalmol. 2023 Mar;107(3):324-330. (PMID: 34656986)
Exp Eye Res. 2014 Jan;118:46-52. (PMID: 24216315)
J Invest Dermatol. 2006 Oct;126(10):2158-9. (PMID: 16983324)
Nat Med. 2011 Nov 20;17(12):1627-35. (PMID: 22101765)
Virchows Arch. 2021 Sep;479(3):551-558. (PMID: 33768319)
Nature. 2001 Nov 1;414(6859):105-11. (PMID: 11689955)
Eye (Lond). 2017 Mar;31(3):379-388. (PMID: 27768120)
Oncol Lett. 2021 Dec;22(6):833. (PMID: 34691259)
Arch Otolaryngol Head Neck Surg. 1992 Nov;118(11):1245-9. (PMID: 1418905)
Ocul Oncol Pathol. 2020 Aug;6(4):226-237. (PMID: 33005611)
Int J Mol Sci. 2021 Aug 06;22(16):. (PMID: 34445161)
Lancet Oncol. 2019 Dec;20(12):e699-e714. (PMID: 31797796)
Asia Pac J Ophthalmol (Phila). 2015 Jul-Aug;4(4):221-7. (PMID: 26147013)
Signal Transduct Target Ther. 2019 Dec 17;4:62. (PMID: 31871779)
Zhonghua Yan Ke Za Zhi. 2022 Mar 11;58(3):205-212. (PMID: 35280029)
Oncol Lett. 2018 Jun;15(6):8206-8214. (PMID: 29805554)
Invest Ophthalmol Vis Sci. 2013 Jan 14;54(1):370-7. (PMID: 23249701)
J Cancer Res Clin Oncol. 2016 Jan;142(1):125-33. (PMID: 26141290)
J Pathol. 2012 Jan;226(2):352-64. (PMID: 21990031)
Int Ophthalmol. 2020 Feb;40(2):343-350. (PMID: 31571090)
Cancer. 2009 Jan 1;115(1):158-65. (PMID: 18988294)
JAMA Ophthalmol. 2015 Oct;133(10):1109-16. (PMID: 26203913)
Eye (Lond). 2023 Mar;37(4):714-719. (PMID: 35347292)
Indian J Ophthalmol. 2007 Mar-Apr;55(2):109-12. (PMID: 17322599)
Br J Ophthalmol. 2011 Feb;95(2):284-7. (PMID: 20813740)
Ophthalmic Plast Reconstr Surg. 2010 Sep-Oct;26(5):366-8. (PMID: 20856079)
Dermatol Surg. 2007 Mar;33(3):333-9. (PMID: 17338692)

0 (Biomarkers, Tumor)

Date Created: 20240927 Date Completed: 20240927 Latest Revision: 20241120

20241120

PMC11573021

10.4103/IJO.IJO_167_24

39331429